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A B S T R A C T
Cancer of the oropharynx has attracted considerable attention in recent years given: (1) an increasing incidence
in selected populations over the past three decades; (2) the discovery of human papillomavirus (HPV) infection
as the driver of the increase, as opposed to the traditional risk factors such as tobacco (smoking and chewing)
and alcohol; and (3) the promise of new prevention and treatment strategies. As a result of such developments,
the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI), convened
the fourth Cancer Seminar meeting in November 2018 to focus on this topic. This report summarizes the pro-
ceedings: a review of recent science on the descriptive epidemiology, etiology, biology, genetics, early detection,
pathology and treatment of HPV-positive oropharyngeal cancer, and the formulation of key research questions to
be addressed.
Introduction
A joint workshop led by the National Cancer Institute (NCI) and the
International Agency for Research on Cancer (IARC) was held in
November 2018 in Rockville, MD, USA, to discuss the state-of-the-sci-
ence of HPV-positive oropharyngeal cancer epidemiology, etiology,
biology, genetics, early detection, pathology and treatment. This per-
spective summarizes the meeting proceedings, including description of
burden of disease, methods for ascertainment, HPV attributable fraction
of disease, epidemiology of oral HPV and HPV-positive OPC, genetics
and genomics, biology of HPV-positive OPC, prevention, and clinical
-aspects.
Of note, several comprehensive reviews on HPV-positive orophar-
yngeal cancer have recently been published. Rather than update these
reviews, we highlight important achievements and focus on key
knowledge gaps and outstanding research questions.
Burden of HPV positive oropharyngeal cancer worldwide
Oropharyngeal cancer (OPC) includes lesions arising from these
anatomic sites and subsites: the base of tongue/lingual tonsil (ICD-10
codes C01.9 and C2.4), palatine tonsil (C9.0, C09.1, C09.8, C09.9),
oropharynx (C10.0 to C10.9, excluding C10.1, C110.4-7), pharyngeal
tonsils (C11.1), soft palate (C05.1), uvula (C05.2), pharynx not other-
wise specified (C14.0), and Waldeyer ring (C14.2) [1] Approximately
100,000 new cases of oropharyngeal cancer occur annually worldwide;
regional differences in incidence can vary between 5/100,000 and 10/
100,000 (for all ages) [2]. Despite notable declines in tobacco use, or-
opharyngeal cancer incidence has increased over recent decades in
several high-income countries (e.g., Australia, Canada, Denmark,
Japan, Netherlands, Norway, Sweden, Taiwan, USA, and the UK), in-
itially among men < 60 years [1,3,4]. In many countries, molecular
epidemiologic studies have established HPV infection as the cause of
rising incidence [5–7]. It is hypothesized that oral HPV exposure in-
creased as a result of changes in sexual behavior in birth cohorts from
the 1930s to 1950s and decreases in tonsillectomy rates (which results
in more tissue available for infection by the virus) account for the ob-
served rise in HPV positive oropharyngeal cancer incidence in men
since the 1990s [1,8,9].
In the USA, studies have documented changes in the oropharyngeal
cancer incidence trajectory over the past decade, moderation of the
original increases among mid-life individuals (ages 45–60 years), sus-
tained increases among older ages (ages 65+ years), and the emer-
gence of a modest rise in incidence in women [9,10]. It remains to be
seen whether these emerging oropharyngeal cancer incidence trends
will continue to persist in the USA and/or begin to manifest in other
parts of the world (Table 1).
Methods for assessment of HPV presence in oropharyngeal cancer
Current methods for testing oropharyngeal cancer tumor tissues
include HPV DNA detection, quantitative type-specific PCR, HPV DNA
sequencing, detection of HPV E6/E7 mRNA, in-situ hybridization, and
immunohistochemistry [11–15]. In studies that have compared HPV
detection methods in oropharyngeal cancers show that the proportion
that are positive for HPV is overestimated by HPV DNA genotyping
alone but the combination of more rigorous markers tend to produce
lower estimates for attributable fractions [11,12,16].
HPV attributable fraction in oropharyngeal cancer
Current estimates vary greatly. Between 5% and 80% of orophar-
yngeal cancers are attributable to HPV, with substantial geographic
variability [17]. Regions with high HPV attributable fractions include
northern Europe and the USA [11,16], which reflects the relative
burden of tobacco-/alcohol-attributable oropharyngeal cancer as well
as prevalent sexual practices. Worldwide, HPV16 causes the majority
(> 90%) of HPV positive oropharyngeal cancer, followed by HPV33,
HPV35 and HPV18 [11,18]. In contrast to cervical cancer, HPV33 is the
second most frequent HPV type in oropharyngeal cancer and HPV18 is
far less frequent. Robust data on HPV attributable fractions and trends
over time are not available for many countries.
Epidemiology of oral HPV infection and HPV positive
oropharyngeal cancer
To date, most published studies on the epidemiology of oral HPV
infection suggest that oral HPV infection, the underlying cause of HPV
positive oropharyngeal cancer, is rare in the general population—1%
prevalence for HPV16 and < 5% prevalence for all other oncogenic
HPV types, which most likely reflects the presence of subclinical or
asymptomatic infections [19,20]. While oral HPV prevalence tends to
be significantly higher among HIV populations, these increases do not
translate to a substantially higher burden of oropharyngeal cancer in
this population (i.e.: standardized incidence ratio < 3.0) [21].
Oral HPV is primarily transmitted through oral sex with an infected
partner; consequently, infection prevalence is strongly associated with
the number of lifetime as well as recent oral sexual partners [19]. Oral
HPV prevalence displays a bi-modal age-pattern, with an initial peak at
ages 25–30 years and a second peak at ages 55–60 years. It is unknown
if this second peak reflects recent acquisition, reactivation of latent
(immune controlled) infections due to age-related immune-senescence,
or birth-cohort effects. Both oral HPV prevalence and HPV positive
oropharyngeal cancer are more common in men [5,19,22]. The reasons
for the male predominance is unknown. Current hypotheses include a
heightened immune-susceptibility in males, e.g. because of less fre-
quent seroconversion after genital infection, as well as greater trans-
mission of HPV through the performance of oral sex on females [19,22].
The rates of incidence and persistence, and the predictors of HPV oral
infection remain poorly characterized, mainly due to a paucity of stu-
dies of the natural history of oral HPV infection [23].
Smoking and alcohol, the traditional risk factors for oropharyngeal
cancer, appear to be independently associated with risk of HPV positive
oropharyngeal cancer. However, the interaction of these risk factors
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with HPV remains unclear [24–30]. Little is known regarding the as-
sociation of other established (tobacco/betel-quid chewing) or emer-
ging factors (oral hygiene, oral microbiome) with risk of HPV positive
oropharyngeal cancer.
Key outstanding research questions pertaining to the epidemiology
of oral HPV/HPV positive oropharyngeal cancer include the confirma-
tion and elucidation of the observed bimodal age-prevalence of oral
HPV infection; male predominance; characterization of the natural
history of oral HPV, with an emphasis on the steps between initial in-
fection and the later development of cancer; and investigation of the
role of established and emerging risk factors for HPV positive or-
opharyngeal cancer (Table 1).
Genetics and genomics
Recent genomic studies of HPV positive oropharyngeal cancer have
focused on the tumor, host, and variation within the oncogenic virus.
The Cancer Genome Atlas (TCGA) study of head and neck cancers in-
cluded only 33 oropharyngeal cancer cases, the majority of which were
HPV positive [31]. A subsequent comprehensive analysis of a larger
dataset of HPV positive tumors demonstrated multiple genomic features
that distinguish these tumors from HPV negative cancers [32]. These
include unique mutation signatures, recurrent somatic mutations pro-
files, candidate driver genes, regions of subchromosomal gains and
losses and gene expression profiles [31,32]. Patterns of chromosomal
loss and gain for HPV positive tumors are consistent with other
Table 1
State-of-the-science and outstanding research questions on HPV positive oropharynx cancer.
Area State-of-the-science Key research areas/questions
Burden – OPC incidence rates of 5–10/100,000
– HPV established as the cause of rising incidence in men (age 50 to 60) in
developed countries
– Geographic variability in contemporary HPV attributable proportions
(5%-80%), with higher proportions (> 70%) in North America, northern
Europe, and other countries
– Emerging data on plateauing of rising incidence in young men in high
income countries with now rising incidence in older ages, early signs of
rising incidence in women, and rising incidence in additional countries .
– Is the rising incidence a phenomenon restricted to men (aged 50 to 60) in
high income countries?
– Have incidence rates in high income countries peaked?
– Is HPV positive OPC increasing in low/middle income countries?
Epidemiology – Oral HPV infection is primarily sexually transmitted
– Prevalence follows a bimodal pattern with peaks at ages 25–30 and
55–60 years
– Oral HPV prevalence and HPV positive OPC are more common in men
– Presence of antibodies to HPV16E6 associated with a > 100-fold
increased risk of OPC
– Association of traditional risk factors (tobacco and alcohol) and emerging
OPC risk factors remains poorly quantified, as does interaction of HPV with
these risk factors
– Identification of the reasons for the bimodal age-prevalence pattern as
well as the male predominance of oral HPV infection/-associated OPC
– Estimation of the main effects and interactions of established and
emerging factors (oral health/microbiome) towards risk of HPV positive
OPC
– Characterization of the natural history of oral HPV infection




– HPV positive OPC characterized by different somatic mutational profiles
compared to HPV negative OPC
– Risk of HPV positive OPC associated with the HLA haplotype DRB1*1301
– DQA1*0103 – DQB1*0603
– Characterization of somatic changes in HPV positive OPC in large,
representative studies
– Further elucidation of the associations of host genetic polymorphisms
with HPV positive OPC risk
– Investigation of the role of viral genomics in risk of HPV positive OPC
across geographic and ancestral backgrounds
Biology – HPV16 causes over 90% of HPV positive OPC
– HPV positive OPC arise from the specialized crypt epithelium in the
lingual and palatine tonsils
– High PD-L1 expression in the crypt epithelium provides immunological
refuge for the infection/tumor
Natural history of oral HPV infection, encompassing establishment of
infection and progression to cancer, remains poorly characterized
– Characterization of the natural history of HPV induced carcinogenesis in
the oropharynx, including estimation of latency and identification of
precancerous states
– Discovering the reasons for the unique susceptibility of the tonsil crypt
epithelium to HPV16-carcinogenesis
– Development of model systems to study HPV induced carcinogenesis in
the oropharynx
– Elucidation of the postulated immune-evasion processes in the crypt
epithelium and development of therapeutic strategies targeting them
Prevention – Prophylactic HPV vaccination has high efficacy against oral HPV infection
prevalence
– Markers of HPV exposure, such as systemic HPV16 E6 antibodies and oral
HPV16 DNA, are strongly associated with risk of HPV positive OPC
– Secondary prevention and early detection through screening is not
currently feasible due to lack of an identifiable HPV induced precancerous
lesion, screening modalities, and risk-mitigation strategies
– Understanding the relevance of the second age-peak in oral HPV
prevalence for risk of HPV positive OPC
– Estimation of the effectiveness of an extended upper age-limit for catch-
up HPV vaccination
– Discovery of HPV induced precancer in the oropharynx and the
identification and validation of screening methods and treatment
strategies for secondary prevention and early detection
Clinical care – HPV positive OPC patients have higher survival than HPV negative OPC
patients
– HPV testing through p16 immunohistochemistry is currently
recommended for all newly-diagnosed OPC patients and patients with
unknown head and neck primaries
– Revised cTNM and pTNM staging of HPV positive OPC in the AJCC 8th
edition
– Numerous investigations underway to determine optimal treatment de-
escalation for HPV positive OPC patients
– Identification of markers to improve the accuracy of tumor HPV
determination beyond p16 immunohistochemistry
– Identification and incorporation of additional prognostic factors for
improved staging of HPV positive OPC
– Development and validation of prediction models to identify patients
who could benefit from de-intensified treatments
– Identification of optimal treatment protocols for HPV positive OPC
patients that preserve disease control and reduce short-and-long-term
treatment-related toxicities
– Follow up biomarkers to detect recurrences in HPV driven OPC
OPC, oropharynx cancer.
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squamous cell carcinomas [31,33–35]. When compared to HPV nega-
tive oral cancers, HPV positive cancers have significantly more frequent
gains in 3q and losses of 11q, 13q, 14q, 16p and 16q [32]. By contrast,
common amplifications of chromosome 7p and deletions of 9p con-
taining the EGFR and CDKN2A genes, respectively, are rare in HPV
positive oropharyngeal cancer when compared to other squamous
carcinomas. The initial reports of a differential dependence on driver
gene alterations extends to frequent amplifications of the transcription
factor E2F1 and deletions or inactivating mutations of TRAF3. How-
ever, E2F1 is one of many genes whose expression is significantly al-
tered by amplification in this chromosomal region. Notably, TRAF3 and
E2F1 alterations frequently found in HPV positive oropharyngeal
cancer are rare in cervical cancer. Emerging data also suggest a role for
viral integration and structural alterations of the viral genome [36].
While these observations provide an initial assessment of the landscape
of somatic events, ongoing larger studies will develop a more com-
prehensive genomic profile of HPV positive oropharyngeal cancer.
Germline genetic factors also play an important role in susceptibility
to HPV positive oropharyngeal cancer and could also explain differ-
ences in response to treatment and survival. The human leukocyte an-
tigen (HLA) region (6p21.3) influences susceptibility to HPV positive
oropharyngeal cancer [37]. Specifically, a four-fold protective effect
was observed with the HLA haplotype DRB1*1301 - DQA1*0103 -
DQB1*0603 for HPV positive but not HPV negative oropharyngeal
cancer [37]. This haplotype has also been reported to be strongly
protective against cervical cancer, which suggests specificity for HPV
positive cancers. These observations imply a role for major histo-
compatibility class 2 genes in the recognition and elimination of HPV
infection.
Analysis of the HPV genome is a rapidly evolving field that has
provided insights into the molecular epidemiology and basic biology of
HPV induced cervical cancer [38–40]. Recent studies show that HPV16
variants strongly influence risk of different histologic subtypes of cer-
vical cancer and conservation of E7 oncogene is essential for carcino-
genesis [38–40]. HPV genomics also influences risk of cervical cancer in
distinct race/ethnic groups [39,41] and worldwide HPV type distribu-
tion [42,43]. Future studies of HPV genomics and oropharyngeal cancer
are needed to address the unique susceptibility of the oropharynx to
HPV16 induced carcinogenicity as well as explain the differences in
HPV attributable fractions due to geographic or ancestral backgrounds.
Biology of HPV positive oropharyngeal cancer
HPV positive oropharyngeal cancer primarily arises from the spe-
cialized reticulated crypt epithelium in the lingual and palatine tonsils
[44,45]. The stratified squamous surface epithelium of the tonsils in-
vaginates into multiple crypts and transitions into the reticulated crypt
epithelium. Little is known regarding the HPV induced carcinogenic
process in the crypt epithelium, but it is anticipated that crypt epithe-
lium facilitates virus infection by virtue of its reticulated structure, and
that epithelial cells at this site support deregulated viral gene expres-
sion because they are controlled by different regulatory pathways than
those that normally regulate the epithelial basal layer [46].
The unique architecture of the tonsillar crypts explains several
clinical and histopathologic features of HPV positive oropharyngeal
cancer [44,45]. HPV positive oropharyngeal cancer often retains the
appearance of the reticulated epithelium lining the tonsillar crypts (i.e.
permeating lymphocytes, basaloid cells), and thus might best be re-
garded as highly differentiated tumors rather than poorly differentiated
when the crypt epithelium is used as a reference point of tumor dif-
ferentiation. Although HPV positive oropharyngeal cancers are routi-
nely characterized as non-keratinizing morphology, this reflects the
histology of the normal tonsillar crypt [44,45]. Importantly, the ton-
sillar crypt epithelium is characterized as a discontinuous basement
membrane [44,45]. This compromised barrier to tumor invasion may
provide ready access of even small tumors to the underlying
lymphatics. Indeed, HPV positive oropharyngeal cancers are char-
acterized in TNM staging by lower T-category and greater nodal in-
volvement when compared to HPV negative oropharyngeal cancer [47].
Such access of oropharyngeal tumor cells to regional lymph nodes is
exemplified by the greater nodal involvement of squamous cell carci-
noma originating in the oropharynx vs. the oral cavity. Although the
occurrence of a virally-induced cancer in an immune-rich environment
appears paradoxical, the crypt epithelium has high PD-L1 expression,
which provides a mechanism for immune-evasion of the infection/
tumor [44,45].
Key research questions pertaining to the biology and carcinogenesis
of HPV positive oropharyngeal cancer include identification of reasons
for the unique susceptibility of the crypt epithelium to HPV16-mediated
carcinogenesis, development of model systems to study the carcino-
genic processes in the oropharynx, elucidation of the postulated im-
mune-evasion processes and identification of targeted therapeutic
strategies.
Prevention of HPV positive oropharyngeal cancer
Although the current prophylactic HPV vaccines are not licensed for
the prevention of oral HPV infections or oral cancers, vaccination likely
confers strong (> 90%) protection against oral HPV infection pre-
valence, as evidenced in a post-hoc analysis of a randomized clinical
trial of the bivalent HPV vaccine and in a US-representative surveil-
lance study [48–50]. The World Heath Organization focuses their HPV
recommendation on females given the overwhelming burden of HPV-
associated cervical cancer; of the 630,000 new HPV-related cancers
annually, > 85% are cancers of the cervix [51]. However, some coun-
tries with adequate cervical cancer screening programs now have si-
milar burden of HPV disease in females and males. Consequently,
gender neutral vaccination is recommended for adolescents/young
adults. In the United States, for example, children aged nine to 26 years
are recommended to receive the HPV vaccine, with an option for shared
clinical decision making to the age of 45.[52] Importantly, while HPV
vaccines have demonstrated oral HPV vaccine efficacy when adminis-
tered to young adults, it is unknown whether HPV infections detected at
older ages are incident or re-ermegent latent infections for which the
vaccine would not protect; age at causal infection acquisition has not
been modeled. Consequently, the effectiveness of an extended age
catch-up vaccination program for the prevention of HPV positive or-
opharyngeal cancer is unclear, even if high vaccine efficacy is demon-
strated at older ages.
Screening for secondary prevention and early-detection is being
considered as a prevention strategy for HPV positive oropharyngeal
cancer among older vaccine-ineligible individuals [53,54]. Current re-
search efforts are focused on addressing the fundamental principles of
screening and include [8,53]: 1) who to screen (identification of bio-
markers and risk-stratification tools); 2) what to screen for (identifi-
cation of an HPV induced precancer/early-cancer in the oropharynx);
3) how to screen (identification of screening modalities); and 4) how to
manage screen-positive individuals (identification of appropriate
treatments for precancer/early-stage cancer).
Recent studies have made considerable progress on the identifica-
tion of biomarkers, such as systemic HPV antibodies or oral HPV DNA
[55,56]. Antibodies against the oncoprotein E6 are considered markers
of HPV positive oropharyngeal cancer. Antibodies are strongly asso-
ciated with HPV induced tumors at or prior to cancer-diagnosis (> 100-
fold risk). Seropositivity is rare (< 1% prevalence) in cancer-free in-
dividuals [55–58]. Specifically, HPV16 E6 antibody seropositivity has
been reproducibly demonstrated to have high sensitivity (> 90%) and
specificity (> 99%) for the diagnosis of concurrent HPV16-positive
oropharyngeal cancer (tumor-HPV positivity by the gold-standard of
E6*I mRNA-positivity) [59]. E6-seropositivity precedes cancer diag-
nosis by 5–15 years, underscoring its potential utility as a screening
biomarker. HPV DNA detection in oral rinse samples among patients
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with HPV-driven tumors (i.e., biomarker sensitivity) ranged from 30 to
77%; the range restricting to HPV type 16 was 45 to 82% [60–63]. A
recent study demonstrated oral HPV DNA detection was 81% sensitive
and 100% specific for the diagnosis of recurrent HPV 16-positive or-
opharyngeal cancer [64].
Despite the promising estimates for sensitivity and specificity, the
current value these markers have for population-wide oropharyngeal
cancer screening remains low because positive predictive value (PPV) is
predicated on the prevalence of the disease. The estimated PPV for 10-
year oropharyngeal cancer risk by either marker is low (< 10%) and
the number needed to be screened for the identification of one HPV
positive oropharyngeal cancer is approximately 13,000 [65]. In addi-
tion to the low PPV, there are additional limitations that make
screening for HPV positive oropharyngeal cancer unfeasible. First, an
HPV-induced precancer or early-stage cancer akin to carcinoma in-situ
has yet to be described. Second, currently available imaging modalities,
such as ultrasound and MRI, remain unproven for the identification of
early-stage cancer. Third, there are no risk-mitigation strategies for the
prevention of cancer through treatment of precancer/early cancer or
reduction in morbidity/mortality through the treatment of early-cancer
[8,54,66].
Collectively, these considerations argue against screening for HPV
positive oropharyngeal cancer in clinical settings at this time. Yet,
several risk-stratification tools, such as E6-seropositivity, are under
active investigation and could enable cost-efficient design of studies to
address the current challenges of identification of early stage HPV in-
duced cancer, viable screening modalities, and risk-mitigation strate-
gies.
Clinical aspects of HPV positive oropharyngeal cancer
HPV positive oropharyngeal cancer patients experience a 50% to
80% reduction in five-year risk of progression and death when com-
pared to HPV negative oropharyngeal cancer patients (45% and 50%,
respectively) [67–69]. The improved prognosis, coupled with the ra-
pidly rising HPV positive incidence, has prompted the introduction of
routine HPV testing of tumor samples, novel clinical and pathologic
staging systems, and clinical trials of modified therapies for this patient
population [70,71].
The College of American Pathologists and the American Society of
Clinical Oncology recommend routine HPV testing of tumors from all
newly-diagnosed oropharyngeal cancer patients and patients with un-
known head and neck primaries to guide patient counseling and clinical
trial design [70,71]. The recommended method for determination of
tumor HPV status (primary tumor tissue) is p16 immunohistochemistry
staining, though it has relatively low (85%) specificity. Oncogenic HPV
testing through DNA or RNA in-situ hybridization may be re-
commended by clinicians, pathologists, or researchers.[70,71] Further,
tumor HPV status is now included in the 8th edition of the American
Joint Committee on Cancer (AJCC)/Union for International Cancer
Control (UICC) staging manual [70,71].
The emergence of HPV-positive oropharyngeal cancer has led to the
introduction of revised staging-systems [72,73]. Specifically, the AJCC/
UICC 7th edition of TNM staging (TNM-7) for HPV positive orophar-
yngeal cancer was neither predictive of a patient’s survival experience
nor discriminatory of survival across stages I-IV. This was mainly due to
lack of prognostication among TNM-7 N1-N2b subset which subse-
quently has been re-termed as cN1 in the 8th edition TNM (TNM-8)
[72–75]. Thus, the AJCC recently introduced novel clinical and pa-
thologic TNM classification in the 8th edition [72–74]. For HPV posi-
tive patients (determined by p16 immunohistochemistry staining), the
clinical staging (cTNM) comprises stage I (T1-T2 and N0-N1); stage II
(T3, N2); stage III (T4, N3), and stage IV (M1 disease). Importantly, this
8th TNM edition is predicted to reclassify nearly 50% M0 patients with
stage IV disease by the 7th edition (TNM-7) as stage I disease [72–74].
The novel pathology TNM staging (pTNM) comprises stage I (pT1-T2,
≤ 4 nodes); stage II (pT1-T2, 5 + nodes); and stage III (pT3-T4,
5 + nodes) [72–74]. Recent validation analyses of the novel staging
systems show improved discrimination of survival across stages for
HPV-positive patients [76]. There is, however, controversy pertaining
to prognostic differences in cTNM vs. pTNM as well as the lack of
consideration in pTNM for laterality of nodes, radiographic extranodal
extension and other patient factors [77].
Current treatment guidelines are similar for HPV positive and HPV
negative oropharyngeal cancer patients [78,79]. However, in view of
the typical HPV positive oropharyngeal cancer patient profile (i.e. good
performance status, fewer co-morbidities) and high survival, the field is
investigating treatment de-intensification strategies to reduce treatment
toxicities, while preserving disease control [80–85]. These strategies
include use of immunotherapy (nivolumab, pembrolizumab, or durva-
lumab for cisplatin-ineligible/resistant patients), reduction in radiation
dose (surgery + radiotherapy or induction chemotherapy + radio-
therapy), and surgery-alone for very-low-risk patients [80–84,86–88].
Key research questions pertaining to clinical aspects of HPV positive
oropharyngeal cancer include further development of risk stratification
tools, increased precision of diagnostic modalities, improvements in the
accuracy of tumor HPV determination beyond p16 im-
munohistochemistry, improvements in staging scheme to incorporate
additional prognostic variables, such as extracapsular spread of disease,
and importantly, the identification of patients most likely to benefit
from treatment de-escalation.
Conclusion
Research over the past 20 years has established HPV positive or-
opharyngeal cancer as an important disease entity in many countries,
with unique epidemiologic, molecular, pathologic, and clinical char-
acteristics. Yet, as outlined in this meeting report, many key questions
remain. Ongoing multidisciplinary collaborations across laboratory
scientists, geneticists, epidemiologists, and clinicians hold promise for
improved characterization of the burden, etiology, and natural history
of HPV positive oropharyngeal cancer, and ultimately, the identifica-
tion of effective prevention (beyond the current vaccination schedules
which will only have an impact after several decades) and treatment
strategies for this disease in the near future.
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